USF Health, FORCE receive $1.45 million from PCORI to advance and expand clinical research network

A team led by the University of South Florida (USF Health) Morsani College of Medicine and the leading national hereditary breast and ovarian cancer advocacy organization, FORCE (Facing Our Risk of Cancer Empowered) received a $1.45-million funding award for a three-year project from the Patient-Centered Outcomes Research Institute (PCORI) to continue to advance and expand the ABOUT Network as part of the second phase of PCORnet: the National Patient-Centered Clinical Research Network.

The ABOUT Network (American BRCA Outcomes and Utilization of Testing Patient-Powered Research Network) focuses on hereditary cancer and is one of 34 health data networks recently approved for a total of $142.5 million from PCORI to support PCORnet. PCORnet is a large, collaborative research initiative designed to link researchers, patient communities, clinicians, and health systems in productive research partnerships to leverage the power of large volumes of health data maintained by the partner networks. PCORnet will enable the nation to conduct clinical research more quickly and less expensively than is now possible and will ensure that research focuses on the questions and outcomes that matter most to patients and those who care for them.

The team is led by co-principal investigators Rebecca Sutphen, MD, professor of genetics at the USF Health Morsani College of Medicine, and Dr. Sue Friedman, founder and executive director of FORCE. The Michigan Department of Health and Human Services Genomics and Genetic Disorders Section and advocacy organizations Black Women's Health Imperative, Ovarian Cancer National Alliance, Sharsheret and Young Survival Coalition are also partners in the next phase of the network.

"Our USF and FORCE teams bring highly complementary expertise in research and advocacy to this effort and we anticipate that together we will play an important role in shaping the future of hereditary cancer research to improve health for the high-risk community," said USF's Dr. Sutphen. "We were honored to be selected as an inaugural member in Phase I of the PCORnet National Clinical Research Network and are excited to continue this important work in Phase II."

"FORCE's continued involvement in this collaboration will further advance our mission to improve the lives of people and families affected by hereditary breast and ovarian cancer," said FORCE's Dr. Friedman. "Our participation in PCORnet will provide members of our community with an unprecedented opportunity to establish goals, identify unmet needs, and shape the priorities for comparative effective research."

"We're pleased that the ABOUT Network has been approved for this funding support to continue our productive mutual efforts to build what we intend to be a premier national resource for conducting high-quality, patient-centered clinical research," said PCORI Executive Director Joe Selby, MD, MPH. "I greatly appreciate the contributions of all the PCORnet partners during Phase I, which readied PCORnet for a robust start on an exciting second phase of expansion and the launch of several research studies."

The funding award to the ABOUT Network has been approved by PCORI's Board pending completion of a business and programmatic review by PCORI staff and negotiation of a formal award contract. PCORI is an independent, non-profit organization authorized by Congress in 2010 to fund research that will provide patients, their caregivers and clinicians with the evidence-based information they need to make better-informed health care decisions. PCORI is committed to continuously seeking input from a broad range of stakeholders to guide its work.

Source:

University of South Florida (USF Health)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Experimental drug benefits some patients with advanced kidney cancer